Ribbon Acquisition Corp Rights
RIBBR
NASDAQ Global Select0.18
USD
- -
- -
CIK
0002035016
ISIN
KYG7552W1179
Return %
Stock
S&P500
1Y
-16.19
26.53
3Y
3.53
76.60
5Y
3.53
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Angshuman Ghosh
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Central Park Tower La Tour Shinjuku, Room 3001, 6-15-1 Nishishinjuku Tokyo Japan 160-0023
- IPO Date
- Jan 16, 2025
- CIK
- 0002035016
- Website
- ribbonacquisitioncorp.com
- Similar Companies
- Business
- Ribbon Acquisition Corp is a special purpose acquisition company (SPAC) formed in 2024 and headquartered in Tokyo, Japan. The company operates primarily to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses. Ribbon Acquisition Corp does not generate revenue from operating activities directly but provides capital through its IPO proceeds and other financing to facilitate business combinations. A significant recent development is the announcement in mid-2025 of a definitive business combination agreement with DRC Medicine Ltd, a Tokyo-based healthcare and biotechnology company. This transaction is designed to take DRC Medicine public on the NASDAQ Global Market, with an implied initial equity value of approximately $422.15 million and anticipated cash proceeds of around $50 million for funding clinical trials and operations. DRC Medicine specializes in the design and manufacture of AI-powered allergy and infection diagnostic kits and protective face masks, including products using Hydro Silver Titanium® technology. The merger represents Ribbon Acquisition Corp's first major operational shift from a blank check company to an active participant in the healthcare technology sector, targeting growth through innovative medical devices and diagnostics. Alongside this merger, Ribbon Acquisition Corp separated trading of its ordinary shares and rights in early 2025, enhancing liquidity and investor flexibility. The company is led by CEO Angshuman (Bubai) Ghosh and CFO Zhiyang (Anna) Zhou, leveraging extensive financial and operational expertise to support these strategic initiatives. Ribbon Acquisition Corp focuses on healthcare and biotechnology markets primarily in Japan and the United States through its transaction with DRC Medicine Ltd. The company remains committed to pursuing further business combinations that align with its growth strategy within promising industry segments.